DAM
VIVO

DLD Asset Management’s Meridian Bioscience Inc VIVO Stock Holding History

DLD Asset Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-250,000
Closed -$7.88M – 177
2022
Q3 		$7.88M Buy
+250,000
New +$8.1M 0.61% 52

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DLD Asset Management's VIVO Position: Q4 2022 in Review

DLD Asset Management sold out of Meridian Bioscience Inc (VIVO) in Q4 2022, closing a stake of 250,000 shares — an estimated $7.88M sold.

DLD Asset Management first reported a position in VIVO in Q3 2022 and held it in 1 quarter. The position peaked at $7.88M in Q3 2022. 218 funds tracked by Wall St. Rank hold VIVO as of Q4 2022.

  • DLD Asset Management reported no remaining Meridian Bioscience Inc position as of Q4 2022 after selling out during the quarter.
  • DLD Asset Management sold 250,000 Meridian Bioscience Inc shares in Q4 2022, an estimated $7.88M.
  • DLD Asset Management first reported a position in Meridian Bioscience Inc in Q3 2022 and held it in 1 quarter.
  • DLD Asset Management's Meridian Bioscience Inc position peaked at $7.88M in Q3 2022.
  • 218 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2022.

Based on DLD Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.